L9S.F Gyre Therapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
3.82 EUR
Close of Nov 12, 2026
3.52 7.65
Market cap
EUR 418M
P/E
-
P/B
4.69x
ROE
-28.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is L9S.F undervalued?

Graham number

The Graham number of Gyre Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gyre Therapeutics, Inc. fundamental analysis

No fundamental analysis for Gyre Therapeutics, Inc. yet.

Gyre Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Pha…

Full company profile